Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285265 | 0.86 | NR1H4 (0.48) | ATMNR1H4NTSR1RXFP1RCE1 | |
| SCHEMBL5166363 | 0.84 | ATM (0.54) | ATMNR1H4NTSR1 | |
| SCHEMBL5166559 | 0.76 | CRHR1 (0.49) | ATMNR1H4NTSR1RXFP1RCE1 | |
| SCHEMBL5165211 | 0.75 | ATM (0.54) | ATMNR1H4NTSR1L3MBTL1 | |
| SCHEMBL4476462 | 0.74 | NR1H4 (0.68) | ATMNR1H4 | |
| Hydrochloric Acid SCHEMBL4495467 | 0.73 | NR1H4 (0.67) | ATMNR1H4 | |
| SCHEMBL5165044 | 0.72 | CREBBP (0.40) | ATMNTSR1RXFP1RCE1 | |
| SCHEMBL4495325 | 0.70 | NR1H4 (0.66) | ATMNR1H4NTSR1RXFP1RCE1 | |
| SCHEMBL6285249 | 0.69 | NR1H4 (0.63) | ATMNR1H4NTSR1RXFP1RCE1 | |
| Hydrochloric Acid SCHEMBL4495356 | 0.69 | NR1H4 (0.64) | ATMNR1H4NTSR1RXFP1RCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1326613-B2 | USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1326613-A1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | ATM 1780/4885NR1H4 3561/4885NTSR1 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.